$70.39
+0.50 (+0.72%)
Performance
1D
—
1W
—
1M
—
3M
-12.34%
6M
-14.23%
1Y
-16.13%
YTD
-12.36%
Open$70.58
Previous Close$69.89
Day High$71.18
Day Low$69.48
52W High$87.39
52W Low$65.21
Volume—
Avg Volume4.12M
Market Cap51.57B
P/E Ratio15.26
EPS$5.02
SectorInsurance
Technical Indicators
Full analysis →
SMA 50
$78.90
Below
SMA 200
$78.77
Below
RSI (14)
49.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Buy
21 analysts
Price Target
+207.4% upside
Current
$70.39
$70.39
Target
$216.38
$216.38
$147.72
$216.38 avg
$328.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 74.53B | 72.13B | 56.93B |
| Net Income | 3.27B | 2.85B | 4.31B |
| Profit Margin | 4.4% | 4.2% | 7.6% |
| EBITDA | 5.53B | 5.09B | 6.27B |
| Free Cash Flow | — | — | 4.53B |
| Rev Growth | +3.3% | +3.3% | +20.2% |
| Debt/Equity | 0.68 | 0.68 | 0.28 |
Dividend
Dividend Yield2.91%
Annual Dividend$2.43
Payout Ratio39.0%
Frequencyquarterly
Ex-DividendApr 10, 2026
Pay DateApr 22, 2026
About Metlife Inc
MetLife, Inc. is one of the world's largest insurance and financial services companies, headquartered in New York, New York, providing life insurance, annuities, employee benefits, and asset management products to individuals, small businesses, and large corporations. The company operates in more than 40 countries and serves hundreds of millions of customers and pension participants through its United States and International segments. MetLife is one of the leading providers of group benefits in the United States, offering dental, vision, disability, and life insurance through employers. Its global presence spans the Americas, Asia, Europe, the Middle East, and Africa.
Insurance Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| CB | Chubb Ltd | $323.21 | -0.74% | 12.2 | 125.86B |
| PGR | Progressive Corp | $202.84 | -1.63% | 10.5 | 118.75B |
| MRSH | Marsh & Mclennan Cos | $174.20 | +0.64% | 21.5 | 89.56B |
| MFC | Manulife Financial Corp | $34.59 | +0.46% | 13.6 | 78.82B |
| AON | Aon Plc-Class A | $321.45 | -1.71% | 19.6 | 72.58B |
| TRV | Travelers Cos Inc/The | $290.59 | -0.83% | 10.5 | 66.09B |
MET Frequently Asked Questions
What does MetLife do?
MetLife sells life insurance, annuities, and employee benefits to individuals and corporations across the United States and a large international footprint spanning Latin America, Asia, Europe, and the Middle East. The company's Group Benefits segment sells life, disability, dental, and vision products to employers as workplace benefits. Its Retirement Income Solutions segment sells annuities and pension risk transfer products, where MetLife takes on retirement obligations from corporations seeking to offload pension liabilities — a growing market as defined-benefit plans mature.
Is MET stock a good investment?
MetLife's investment portfolio — the asset base backing its insurance liabilities — benefits when interest rates rise, as reinvested premiums earn higher returns and new annuity products become more attractive. The company has simplified its portfolio, divesting its U.S. retail life insurance arm (now Brighthouse Financial) to focus on higher-return institutional and group businesses. Book value per share growth and return on equity are the primary metrics MetLife management emphasizes. The international segment introduces emerging market currency and regulatory risk alongside growth potential.
Who are MetLife's main competitors?
Prudential Financial is MetLife's closest peer, competing across group insurance, individual life, and retirement products in both domestic and international markets. Principal Financial Group competes in group benefits and retirement services. Lincoln National competes in group life, disability, and annuities. Aflac is a competitor in supplemental insurance sold at the workplace. In the pension risk transfer market, Prudential, Legal & General America, and Pacific Life compete for large-scale transactions from corporate pension plan sponsors.
Does MetLife pay dividends?
MetLife has paid a quarterly dividend for many years and increases it gradually in line with earnings growth. The yield is one of the higher ones in the life insurance sector, reflecting a balance between returning capital to shareholders and maintaining the surplus levels that regulators and rating agencies expect insurers to hold. Management supplements the dividend with share repurchases, authorized annually and executed opportunistically depending on market conditions and capital levels. The dividend is viewed as stable barring a significant deterioration in investment portfolio performance.
What is MET's stock price today?
MET is currently trading at $70.39, up 0.72% in today's session. Over the past 52 weeks, the stock has traded between a low of $65.21 and a high of $87.39. The current price represents 23% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
What do Wall Street analysts say about MET?
Among 21 analysts covering MET, the consensus rating is Buy — 15 rate it a buy, 6 hold, and 0 sell. The average price target sits at $216.38, implying 207% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
Is Metlife Inc profitable?
Metlife Inc generated $74.53B in revenue during fiscal year 2026, with $3.27B reaching the bottom line as net income. The net profit margin of 4.4% reflects the competitive nature of its industry.
What is MET's P/E ratio?
MET trades at a P/E ratio of 15.26 on trailing earnings of $5.02 per share. That's roughly in line with the broader market average of ~20-25x. Comparing this multiple against Insurance sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.
How has MET stock performed recently?
Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -12.34% (3M), -14.23% (6M), -16.13% (1Y), -12.36% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether MET is outperforming or lagging the broader market.